IMMUNOCHEMICAL DIAGNOSIS OF CANCER. PROTOTYPING

Cover Page

Cite item

Full Text

Abstract

A prototype of the method of immunochemical detection of different types of solid cancers (primary and recurrent) in the early stages was developed. According to the initial hypothesis, the sera of patients with malignant tumors of different localization and different histological nature, contain different sets of autoantibodies (auto-Ab) of IgG class to many cancer-associated antigens (CA-AG). The content of such auto-Ab differs in cancer patients and patients with non-malignant chronic diseases, which determines the difference in serum immunoreactivity profiles of cancer patients and patients with non-malignant diseases. Confirmation of this hypothesis opens up prospects for the creation of simple and cheap laboratory methods of mass preventive examination of the population for the early detection of different cancers. The confirmation of the hypothesis was obtained. Moreover, even with non-optimal sets of test antigens, with the help of solid-phase ELISA it was possible to achieve sensitivity of 71% and specificity of 68% in the differentiation of blood sera of cancer (lung, stomach, ovary, prostate) and non-cancer patients (chronic inflammatory diseases of the lungs, stomach, ovary, prostate) and nearly 90% in the differentiation of healthy individuals from cancer patients.

About the authors

S Kh Gantsev

BSMU

Department of Surgery and Oncology, Scientific research Institute of Oncology Ufa

A I Pukhalenko

MRC "Immunculus"

Moscow, Russia

A A Romaniukha

Institute of computational mathematics RAS

I A Chulina

Institute of Bioorganic chemistry. M. M. Shemyakin and Yu. Ovchinnikov

Branch Pushchino, Moscow Region

A N Chulin

Institute of Bioorganic chemistry. M. M. Shemyakin and Yu. Ovchinnikov

Branch Pushchino, Moscow Region

A B Poletaev

MRC "Immunculus"; Scientific and Practical Center of Children's Psychoneurology

Email: a-b-poletaev@yandex.ru
Moscow, Russia

References

  1. Дамиров М.М., Тютерева И.Н., Ганцев Ш.Х., Полетаева А.А., Полетаев А.Б., Юсупов А.С. Аутоиммунитет и рак. Новые подходы к ранней диагностике злокачественного роста. Креативная хирургия и онкология, 2011, 3, 89-93.
  2. Дрейпер Н. Р., Смит Г. Прикладной регрессионный анализ. М., Финансы и статистика, 2007.
  3. Полетаев А.Б. Физиологическая иммунология. М., Миклош, 2010
  4. Полетаев А.Б. Иммунохимические маркеры опухолевого роста или как мы можем выявлять рак на ранних стадиях развития. Вестник МЕДСИ, 2011, 12, 19-24.
  5. Полетаев А.Б. Антитела к инсулиновым рецепторам как биомаркеры-предвестники сахарного диабета 2-го типа. Terra Medica, 2013, 71, 1, 22-26.
  6. Полетаев А.Б. Про пьяного и потерянные ключи. Клинич. Патофизиология, 2017, 23, 3, 3-13.
  7. Черезов А.Е. общая теория рака: тканевой подход. М.: изд-во МГУ, 1997.
  8. Backes C., Ludwig N., Leidinger P., et al. Immunogenicity of autoantigens. BMC Genomics 2011, 12:340 doi: 10.1186/1471 -2164-12-340.
  9. Bergenfelz C., Medrek C., Ekström E. et al. Wnt5a Induces a Tolerogenic Phenotype of Macrophages in Sepsis and Breast Cancer Patients. J Immunol. 2012 [Epub ahead of print] PMID: 22547701 [PubMed - as supplied by publisher].
  10. Cameron A.C., Trivedi P.K. Microeconometrics: Methods and Applications. Cambridge; New York: Cambridge University Press; 2005.
  11. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650-1691.
  12. Meroni P.L., De Angelis V., Tedesco F. Future Trends. In: Autoantibodies, (Y. Shoenfeld, M. E. Gershwin, P. L. Meroni. Eds.), 823-826, Elsevier, B.V., 2007
  13. Poletaev A. The Main Principles of Adaptive Immune System Function: Self-Recognition, Self-Interaction, and Self-Maintenance. In: Poletaev A. B., ed. Physiologic Autoimmunity and Preventive Medicine. Sharjah, Oak Park, Bussum: Bentham Science Publishers; 2013, 3-20.
  14. Xie C., Kim H. J., Haw J.G. et al. novel multiplex assay combining autoantibodies plus PsA has potential implications for classification of prostate cancer from non-malignant cases. J. Translational Medicine, 2011, 9, 43-53.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Physical and rehabilitation medicine, medical rehabilitation


 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).